Medical Device Quality Regulation Upgrade: Interpretation of the Latest Sampling Check Results and Compliance Response Guidelines

In 2024, the National Medical Products Administration (NMPA) intensified its regulatory oversight of medical devices, increasing inspection frequency and tightening compliance reviews. Recent sampling checks identified non-compliance in 10 batches across six product categories, including nebulizers, dental burs, and pulse oximeters. Key issues included performance deviations, signal integrity defects, and regulatory misalignment for international manufacturers.

To meet evolving compliance requirements, manufacturers must establish robust quality management systems covering the entire product lifecycle, ensuring traceability, risk control, and adherence to technical standards such as YY/T 0466-2016 and GB 9706.1-2020. International companies should assess their regulatory alignment early to avoid delays in market entry and potential enforcement actions.

National Sampling Check Process: Scientific and Transparent

The NMPA's sampling check process follows internationally recognized quality management standards and includes the following key steps:

1. Sampling Strategy: Based on risk levels and product usage scenarios, randomly select products from the market or inventory for inspection.
2. Testing Standards: According to the "Regulations on the Supervision and Administration of Medical Devices" and industry technical specifications (such as YY/T 0466-2016), conduct multi-dimensional testing of product performance, safety, and labeling information.
3. Result Publication: Make the inspection results public through official channels to ensure transparency and urge companies to make improvements.

In-Depth Analysis of Sampling Check Results: Risk Points and Directions for Improvement

The sampling check for this time found that 10 batches (units) of products do not meet the standard requirements, involving 6 types of products such as nebulizers and pulse oximeters. Here is the core issues classified (for the complete list, check this article):

Classification of core issues Specific products Problem description Risks or Impacts Direction of improvement The performance parameters are not up to standard Medical nebulizers The median particle size of 3 products was outside the standard range This may result in inaccurate patient inhalation doses Optimize the production process parameters, strengthen the factory inspection, and ensure that the particle size distribution meets the YY/T 0466-2016 standard Dental burs Dimensional deviation It affects the accuracy of clinical operation and has potential medical risks High-precision processing equipment is adopted, a dimensional tolerance control system is established, and production equipment is calibrated regularly Signal and data integrity defects Pulse oximeter The signal of 3 products is incomplete May affect the accuracy of oxygen saturation monitoring Upgrade the signal processing algorithm, strengthen the hardware anti-interference design, and pass the third-party EMC (electromagnetic compatibility) test Compliance challenges for international companies Air pressure therapy device (Wonjin Mulsan co., Ltd.) The "pressure under rated voltage" is not up to standard The products do not meet Chinese technical standards Adapt to China's GB 9706.1-2020 standard, carry out localized technical verification, and establish a special compliance team for Chinese regulations

Compliance Strategies in Response to Regulatory Upgrades

In response to the inspection findings, the NMPA has requested relevant provincial departments to take the following measures:

• Administrative Action: Order companies immediately stop selling substandard products and disclose recall information.
• Corrective Action Requirements: Companies must submit a root cause analysis report within 30 days and complete technical improvements within 90 days.

Company Action Guide:

• Risk Assessment and Recall: Develop a recall plan based on the severity of the defects, prioritizing high-risk products.
• Process Optimization: Introduce automated inspection equipment to reduce human error and improve the supplier management system to ensure compliance of raw materials.
• Employee Training: Regularly organize quality management training sessions to strengthen the compliance awareness of all staff.

Strengthening Quality Compliance to Enhance Market Position and Consumer Trust

Competition in the medical device industry has shifted from “product performance” to “quality credibility.” Companies should learn from this inspection and incorporate compliance management into their strategic core to:

• Enhance Market Competitiveness: Gain the long-term trust of healthcare institutions and patients through high-quality products.
• Reduce Legal Risks: Avoid hefty fines or market exclusion due to quality issues.

International Customers: How to Respond to New Chinese Regulatory Requirements?

The Chinese medical device market continues to grow, and navigating its evolving regulatory landscape requires tailored strategies — with the right support, such as Cisema’s expertise, companies can efficiently manage compliance and market entry. International companies should note the following:

• Standard Differences: Technical requirements such as electrical safety and labeling may differ from EU or FDA standards, so early compliance adjustments are essential.
• Localization Support: Collaborate with professional consulting firms like Cisema to quickly access Chinese regulatory interpretations, registration submissions, and quality management system development services.

Further Information

To read the original NMPA announcement about intensifing its regulatory oversight of medical devices, please click here. If you have specific questions about how NMPA's sampling checks may affect you, please contact Cisema.

GET IN TOUCH

🌐 Send us your enquiry📚 Request our whitepapers📣 Sign up for our newsletter